|
T. A. Bogush, S. A. Kaliuzhny, E. A. Dudko, V. Yu. Kirsanov, A. S. Tjulandina, E. A. Bogush, S. A. Tjulandin, M. M. Davydov
Molecular peculiarities of ascitic ovarian
cancer cells revealing by immunofluorescence assay involving flow cytometry
Abstract
Peritoneal dissemination of malignant cells
and their proliferation in ascitic fluid in recurrent III è IV stages of ovarian cancer are phase of the disease characterized
by resistance to various chemotherapy regimens employed for the solid tumor
treatment. Authors supposed that such differences may be due to various
molecular phenotypes of solid and recurrent ascitic ovarian cancer forms. For
validation of this hypothesis comparative study of expression and co-expression
of certain molecular markers was performed on ovarian cancer cells obtained
from solid tumors and ascitic fluids by using immunofluorescence assay
involving flow cytometry. It was established that ascitic cells unlike cells of
solid tumor presented common leucocytic marker CD45 and mesenchymal marker
vimentin additionally to epithelial marker cytokeratin. Hence, besides
inhibition of anoikis (the specific form of epithelial cell death induced in
fluid by the lack of contacts with matrix) ascitic ovarian cancer cells are
characterized by (1) emperipolesis (the intracellular migration of leucocytes
without damage of cancer cells) and (2) phenotype of epithelial-to-mesenchymal transition. Thus, for the first time
it was established that solid and recurrent ascitic ovarian cancer have
clinically significant molecular differences and this fact open up new
opportunities for ovarian cancer treatment.
Key words: immunofluorescence assay, flow
cytometry, ascitic and solid ovarian cancer, CD45, vimentin, cytokeratin.
Copyright (C) Chemistry Dept., Moscow State University, 2002
|
|
